Antimicrobial peptide resistance in Neisseria meningitidis
- PMID: 26002321
- PMCID: PMC4605851
- DOI: 10.1016/j.bbamem.2015.05.006
Antimicrobial peptide resistance in Neisseria meningitidis
Abstract
Antimicrobial peptides (AMPs) play an important role as a host defense against microbial pathogens and are key components of the human innate immune response. Neisseria meningitidis frequently colonizes the human nasopharynx as a commensal but also is a worldwide cause of epidemic meningitis and rapidly fatal sepsis. In the human respiratory tract, the only known reservoir of N. meningitidis, meningococci are exposed to human endogenous AMPs. Thus, it is not surprising that meningococci have evolved effective mechanisms to confer intrinsic and high levels of resistance to the action of AMPs. This article reviews the current knowledge about AMP resistance mechanisms employed by N. meningitidis. Two major resistance mechanisms employed by meningococci are the constitutive modification of the lipid A head groups of lipooligosaccharides by phosphoethanolamine and the active efflux pump mediated excretion of AMPs. Other factors influencing AMP resistance, such as the major porin PorB, the pilin biogenesis apparatus, and capsular polysaccharides, have also been identified. Even with an inherently high intrinsic resistance, several AMP resistance determinants can be further induced upon exposure to AMPs. Many well-characterized AMP resistance mechanisms in other Gram-negative bacteria are not found in meningococci. Thus, N. meningitidis utilizes a limited but highly effective set of molecular mechanisms to mediate antimicrobial peptide resistance. This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
Keywords: Antimicrobial resistance; Efflux pump; Neisseria meningitidis; Phosphoethanolamine modification of lipid A.
Copyright © 2015. Published by Elsevier B.V.
Figures
References
-
- Wilder-Smith A. Meningococcal vaccine in travelers. Current opinion in infectious diseases. 2007;20:454–460. - PubMed
-
- C. Centers for Disease Prevention, Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Morbidity and mortality weekly report. 2010;59:273. - PubMed
-
- Clark TA, Stern E, Pondo T, Arnold K, Harrison LH, Vello M. The effect of quadrivalent (A, C, Y,W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. 16th International pathogenic Neissera conference; Rotterdam, Netherlands. 2008.
-
- Zimmer SM, Stephens DS. Meningococcal conjugate vaccines. Expert Opin. Pharmacother. 2004;5:855–863. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
